Oncocross Applies for KOSDAQ Listing Preliminary Review
The Korea Exchange KOSDAQ Market Headquarters announced on the 8th that it has received the preliminary listing examination application submitted by Oncocross.
Oncocross is a company developing new drugs based on an artificial intelligence (AI) platform, reporting sales of 150 million KRW and an operating loss of 9.99 billion KRW last year. Its industry classification is natural sciences and engineering research and development.
Hot Picks Today
Dramatic Agreement Reached on Eve of Samsung Electronics General Strike... Minister Kim Young-hoon: "Showcased Korea's Strength in Dialogue" (Update)
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
It is subject to a technology special listing, and the lead underwriter for the listing is Mirae Asset Securities.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
